

Phase I (GIHU004)

A PHASE I STUDY TO EVALUATE THE TOLERABILITY AND SAFETY OF A LC002, A DERMAVIR VACCINE, IN HIV-1-INFECTED SUBJECTS CURRENTLY UNDER TREATMENT WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)

Principal Investigator:
Denes Banhegyi, M.D.
St. Laszlo Hospital
Budapest
Hungary

Phase I/II (ACTG 5176)

A PHASE I/II, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF LC002, A DERMAVIR VACCINE, IN HIV-1-INFECTED SUBJECTS CURRENTLY UNDER TREATMENT WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)

Protocol Chair:
Richard Pollard, M.D.
University of California,
Davis Medical Center

Contact Us - Contents © 2005 Genetic Immunity, LLC